Previous 10 |
MALVERN, Pa., March 27, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today ...
MALVERN, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announ...
MALVERN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstru...
MALVERN, Pa., Jan. 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstru...
TELA Bio (NASDAQ: TELA ) is up 5% premarket on announcing preliminary Q4 and FY 2019 revenue. More news on: TELA Bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Preliminary fourth quarter 2019 revenue increased 94%-102% year-over-year to $4.7 million to $4.9 million Preliminary full year 2019 revenue increased 85%-87% year-over-year to $15.3 million to $15.5 million MALVERN, Pa., Jan. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“...
TELA Bio (NASDAQ: TELA ): Q3 EPS of -$22.58 may not be comparable to consensus of -$0.57. More news on: TELA Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Revenue increased 80% year-over-year to $4.0 million Completed initial public offering in November 2019, raising net proceeds of $50.7 million MALVERN, Pa., Dec. 18, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technolo...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 44 th Annual Growth Con...
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Mon...
2024-06-27 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...